CHICAGO, April 29, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Barclays PLC (NYSE:BCS-Free Report), Freddie Mac (OTCBB:FMCC-Free Report), Fannie Mae (OTCBB:FNMA-Free Report), Wells Fargo & Company (NYSE:WFC-Free Report) andPrestige Brands Holdings, Inc. (NYSE:PBH-Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Monday's Analyst Blog:

Barclays Falls on FHFA Settlement

ADRs of Barclays PLC (NYSE:BCS-Free Report) fell nearly 1% following the announcement of a mortgage settlement deal with the Federal Housing Finance Agency (FHFA), the conservator of Freddie Mac (OTCBB:FMCC-Free Report) and Fannie Mae (OTCBB:FNMA-Free Report). The British banking multinational will pay $280 million to compensate for its faulty mortgage activities during the pre-crisis period.

Of the total settlement amount, Barclays will shell out $227 to Freddie Mac and $53 million to Fannie Mae. The deal resolves claims in two lawsuits pertaining to the same issue filed by the FHFA in the U.S. District Court for the Southern District of New York. Notably, the company assured that this would not affect its 2014 results.

Barclays had allegedly sold risky loans worth $4.9 billion to Freddie Mac and Fannie Mae during 2005-07, thereby resulting in huge losses for investors. However, with the tightening of regulations in 2011, Barclays was one of the 18 institutions sued by the FHFA for selling faulty mortgage-backed securities to Freddie Mac and Fannie Mae.

The FHFA continues with its endeavors to protect investors' interest and provide a secured investment environment for them. Since 2011, the agency has reached settlements with 13 financial organizations (including Barclays) and received nearly $16.0 billion as compensation. Additionally, in Nov 2013, Wells Fargo & Company (NYSE:WFC-Free Report), which was not part of the above-mentioned litigation, agreed to pay $335.2 million to resolve similar charges.

Further, though the latest settlement removes a major legal headwind for Barclays, the company is still facing probes and investigations. This might lead to an increase in legal expenses, thereby weighing on the company's profitability in the quarters ahead.

Currently, Barclays carries a Zacks Rank #5 (Strong Sell).

Prestige Brands Acquires Hydralyte

Prestige Brands Holdings, Inc.'s (NYSE:PBH-Free Report) shares shot up 18.13% after the company announced that it entered into an agreement to acquire Insight Pharmaceuticals Corp. for $750 million in cash. The deal is expected to close by Sep 2014.

As per the terms of the agreement, Prestige Brands stands to gain tax attributes with a present value of approximately $100 million. Thus, the effective purchase price will be approximately $650 million.

The transaction will add Insight Pharma's feminine care and other over-the-counter (OTC) healthcare products including Monistat (leading OTC yeast infection treatment brand) to Prestige Brands' portfolio. The acquisition will expand Prestige Brands' presence in the feminine care market in the U.S. and Canada. The deal will be immediately accretive to the company's earnings.

We note that this is the second agreement announced by the company this month. Earlier, the company revealed that it has signed a purchase agreement with Australia-based The Hydration Pharmaceuticals Trust of Victoria to acquire their OTC oral rehydration brand, Hydralyte. The acquisition is slated to close by Jun 2014.

The upcoming acquisition of Hydralyte will help Prestige Brands expand its business in the Austral-Asia region. With Hydralyte's leading-OTC-brand status for oral rehydration following diarrhea, vomiting, fever, heat and other ailments in Australia and New Zealand, the addition of Hydralyte to Prestige Brands' portfolio will be immediately accretive to its earnings.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on BCS - FREE

Get the full Report on FMCC - FREE

Get the full Report on FNMA - FREE

Get the full Report on WFC - FREE

Get the full Report on PBH - FREE

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Logo - http://photos.prnewswire.com/prnh/20101027/ZIRLOGO

SOURCE Zacks Investment Research, Inc.